Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQA2225
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
TQA2225 is a fully human long-acting fibroblast growth factor 21 (FGF21) fusion protein designed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). It utilizes natural human FGF21 as the active form and incorporates a unique linker platform technology to extend its in vivo half-life while preserving biological activity. This approach aims to reduce immunogenicity and improve safety compared to other similar targeted drugs. The mechanism of action involves FGF21 signal transduction, which has demonstrated potential in reversing fibrosis, reducing liver fat, and improving glycemic control. TQA2225 is currently undergoing Phase II clinical trials in China and is considered the fastest-developing product among FGF21-targeted therapies in that region[1][4][6][8].
- Other names
- recombinant human FGF21-Fc fusion protein
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on TQA2225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQA2225.